Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.220
+0.010 (0.83%)
At close: Aug 21, 2026, 4:00 PM EDT
1.230
+0.010 (0.82%)
After-hours: Aug 21, 2026, 7:39 PM EDT
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $47.00M in the twelve months ending June 30, 2026, down -3.25% year-over-year. In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth.
Revenue (ttm)
$47.00M
Revenue Growth
-3.25%
P/S Ratio
1.51
Revenue / Employee
$1,879,880
Employees
25
Market Cap
71.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 59.43M |
| MediciNova | 920.48K |
| Cardiff Oncology | 508.00K |
| iBio, Inc. | 300.00K |
| Serina Therapeutics | 130.00K |
SPRO News
- 11 days ago - Spero Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 11 days ago - Spero Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Spero Therapeutics Earnings release: Q2 2026 - Filings
- 11 days ago - Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - GlobeNewsWire
- 18 days ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - GlobeNewsWire
- 27 days ago - Spero Therapeutics appoints Debra Jeske Zack as chief medical officer - TheFly
- 27 days ago - Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - GlobeNewsWire